HOME Top Market Reports Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray)- Forecast to 2021

Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray)- Forecast to 2021

By: marketsandmarkets.com
Publishing Date: December 2016
Report Code: MD 4803

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global Cancer/Tumor Profiling market is poised to reach USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016, at a CAGR of 19.1% from 2016 to 2021.

The global market is segmented on the basis of technology, technique, application, and region. On the basis of applications, the market is broadly segmented into personalized medicine, biomarker discovery, diagnostics, prognostics, and research applications. The personalized medicine segment is expected to account for the largest share of the global cancer/tumor profiling application market in 2016. Factors attributing to the growth of this segment include better prediction of cancer, and better targeted therapy for the treatment of cancer and reduced probability to adverse drug reactions.

Furthermore, based on technique, the cancer profiling market is segmented into genomics, proteomics, epigenetics, and metabolomics. The genomics segment is expected to account for the largest share of the cancer profiling technique market in 2016. Factors such as increasing investments, grants, and funds by governments; growing research in the field of genomics; and rising application of genomic sequencing in diagnostics are contributing to the growth of this segment.

Based on technology, the global market is broadly divided into next-generation sequencing, quantitative PCR, in situ hybridization, immunohistochemistry, and microarray. The next-generation sequencing segment is expected to account for the largest share of the cancer profiling technology market in 2016. The largest share can be attributed to technology advancements in sequencing platforms, research laboratories and academicians promoting the use of NGS

Major factors fueling market growth are increasing number of cancer cases across the globe, the increasing utility of biomarkers, and availability of funding for cancer research. Factors restraining the market include high capital investments and low benefit ratio for biomarkers used in cancer profiling. Whereas, increasing demand for personalized medicine and point-of-care diagnostic tests in tumor profiling are expected to offer a wide range of growth opportunities for players in the cancer profiling market.

The market is dominated by established players such as Illumina Inc. (U.S.), QIAGEN N.V. (Netherlands), NeoGenomics Laboratories (U.S.), HTG Molecular Diagnostic (U.S.), and Genomic Health Inc. (U.S.).

Stakeholders

  • Hospitals and clinics
  • Research Institutes and clinical research organizations (CROs)
  • Market Research and consulting firms
  • Authorities framing reimbursement policies for use of cancer diagnostics
  • Companies offering platforms/technologies for cancer diagnosis
  • Market research and consulting firms

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

  • The market study doesn’t cover the market size in terms of volume
  • Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
  • Company developments not reported in the public domain are not included in this report

Particular

Scope

Region

  • North America
    • U.S.
    • Canada
  • Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia-Pacific
  • Rest of the World (RoW)

Historical Years

2014

Base Year

2015

Estimated Year

2016-e

Forecast Period

2016-e–2021-p

Revenue Currency

USD ($)

Market Segmentation

This research report categorizes the Cancer Profiling market on the basis of technology, technique, application, and region

Global Cancer Profiling Market, by Application

  • Personalized Medicine
  • Biomarker Discovery
  • Diagnostics
  • Prognostics
  • Research Applications

Global Cancer Profiling Market, by Technique

  • Genomics
  • Proteomics
  • Metabolomics
  • Epigenetics

 Global Cancer Profiling Market, by Technology

  • Next-generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • Quantitative PCR

Global Cancer Profiling Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia-Pacific
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Country-wise analysis of the European cancer profiling market

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
    1.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
                    2.2.2.1 Key Industry Insights
           2.2.3 Assumptions for the Study
    2.3 Macroeconomic Factor Analysis
           2.3.1 Introduction
           2.3.2 Demand-Side Analysis
                    2.3.2.1 Healthcare Expenditure Pattern
           2.3.3 Supply-Side Analysis
                    2.3.3.1 Number of New Product Launches

3 Executive Summary (Page No. - 27)

4 Premium Insights (Page No. - 31)
    4.1 Tumor Profiling Market: Market Overview
    4.2 Geographic Analysis: Tumor Profiling Market, By Technique (2016)
    4.3 Global Tumor Profiling Market Size, By Technology, 2016 vs 2021
    4.4 Global Tumor Profiling Market Size, By Application, 2016 vs 2021
    4.5 Tumor Profiling Market: Geographic Growth Opportunities

5 Market Overview (Page No. - 35)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Number of New Cancer Cases
                    5.2.1.2 Increasing Utility of Biomarkers in Tumor Profiling
                    5.2.1.3 Availability of Funding for Cancer Research
           5.2.2 Restraints
                    5.2.2.1 High Capital Investments and Low Benefit Ratio for Biomarkers
                    5.2.2.2 Lack of Skilled Professionals and Infrastructure
           5.2.3 Opportunities
                    5.2.3.1 Point-Of-Care Diagnostic Tests
                    5.2.3.2 Increasing Demand for Personalized Medicine
           5.2.4 Challenges
                    5.2.4.1 Unclear Regulatory and Reimbursement Scenario

6 Cancer Profiling Market, By Application (Page No. - 43)
    6.1 Introduction
    6.2 Personalized Medicine
    6.3 Diagnostics
    6.4 Biomarker Discovery
    6.5 Prognostics
    6.6 Research Applications

7 Cancer Profiling Market, By Technique (Page No. - 54)
    7.1 Introduction
    7.2 Genomics
    7.3 Proteomics
    7.4 Epigenetics
    7.5 Metabolomics

8 Cancer Profiling Market, By Technology (Page No. - 63)
    8.1 Introduction
    8.2 Next-Generation Sequencing (NGS)
    8.3 Quantitative Polymerase Chain Reaction (QPCR)
    8.4 Immunohistochemistry (ICH)
    8.5 in Situ Hybridization (ISH)
           8.5.1 Fluorescence in Situ Hybridization (FISH)
           8.5.2 Chromogenic in Situ Hybridization (CISH)
    8.6 Microarray

9 Cancer Profiling Market, By Region (Page No. - 73)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
    9.4 Asia-Pacific (APAC)
           9.4.1 China
           9.4.2 Japan
           9.4.3 Rest of Asia-Pacific
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 95)
     10.1 Overview
     10.2 Battle for Market Share: Product Launch Was the Key Growth Strategy Adopted By Market Players Between 2013 and 2016
     10.3 Product Launches
     10.4 Agreements, Collaborations, and Partnerships
     10.5 Acquisitions
     10.6 Others Strategies

11 Company Profiles (Page No. - 100)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     11.1 Introduction
     11.2 Illumina, Inc.
     11.3 Qiagen N.V.
     11.4 Neogenomics Laboratories, Inc.
     11.5 HTG Molecular Diagnostics, Inc.
     11.6 Genomic Health Inc.
     11.7 Caris Life Sciences
     11.8 Helomics Corporation
     11.9 Nanostring Technologies, Inc.
     11.10 Oxford Gene Technology
     11.11 Ribomed Biotechnologies, Inc.

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 143)
     12.1 Insights of Industry Experts
     12.2 Discussion Guide
     12.3 Other Developments
     12.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.5 Introducing RT: Real-Time Market Intelligence
     12.6 Available Customizations
     12.7 Related Reports
     12.8 Author Details


List of Tables (81 Tables)

Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer
Table 2 National Institutes of Health (Nih) Spending, By Type of Cancer (Financial Year 2015)
Table 3 Cancer Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 4 Cancer Profiling Market Size for Personalized Medicine, By Region, 2014–2021 (USD Billion)
Table 5 North America: Tumor Profiling Market Size for Personalized Medicine, By Country, 2014–2021 (USD Billion)
Table 6 APAC: Tumor Profiling Market Size for Personalized Medicine, By Country, 2014–2021 (USD Billion)
Table 7 Tumor Profiling Market Size for Diagnostics, By Region, 2014–2021 (USD Billion)
Table 8 North America: Tumor Profiling Market Size for Diagnostics, By Country, 2014–2021 (USD Billion)
Table 9 APAC: Tumor Profiling Market Size for Diagnostics, By Country, 2014–2021 (USD Billion)
Table 10 Tumor Profiling Market Size for Biomarker Discovery, By Region, 2014–2021 (USD Billion)
Table 11 North America: Tumor Profiling Market Size for Biomarker Discovery, By Country, 2014–2021 (USD Billion)
Table 12 APAC: Tumor Profiling Market Size for Biomarker Discovery, By Country, 2014–2021 (USD Billion)
Table 13 Tumor Profiling Market Size for Prognostics, By Region, 2014–2021 (USD Billion)
Table 14 North America: Tumor Profiling Market Size for Prognostics, By Country, 2014–2021 (USD Billion)
Table 15 APAC: Tumor Profiling Market Size for Prognostics, By Country, 2014–2021 (USD Billion)
Table 16 Tumor Profiling Market Size for Research Applications, By Region, 2014–2021 (USD Billion)
Table 17 North America: Tumor Profiling Market Size for Research Applications, By Country, 2014–2021 (USD Billion)
Table 18 APAC: Tumor Profiling Market Size for Research Applications, By Country, 2014–2021 (USD Billion)
Table 19 Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 20 Tumor Profiling Market Size for Genomics, By Region, 2014–2021 (USD Billion)
Table 21 North America: Tumor Profiling Market Size for Genomics, By Country, 2014–2021 (USD Billion)
Table 22 APAC: Tumor Profiling Market Size for Genomics, By Country, 2014–2021 (USD Billion)
Table 23 Tumor Profiling Market Size for Proteomics, By Region, 2014–2021 (USD Billion)
Table 24 North America: Tumor Profiling Market Size for Proteomics, By Country, 2014–2021 (USD Billion)
Table 25 APAC: Tumor Profiling Market Size for Proteomics, By Country, 2014–2021 (USD Billion)
Table 26 Cancer Profiling Market Size for Epigenetics, By Region, 2014–2021 (USD Billion)
Table 27 North America: Cancer Profiling Market Size for Epigenetics, By Country, 2014–2021 (USD Billion)
Table 28 APAC: Cancer Profiling Market Size for Epigenetics, By Country, 2014–2021 (USD Billion)
Table 29 Cancer Profiling Market Size for Metabolomics, By Region, 2014–2021 (USD Billion)
Table 30 North America: Cancer Profiling Market Size for Metabolomics, By Country, 2014–2021 (USD Billion)
Table 31 APAC: Cancer Profiling Market Size for Metabolomics, By Country, 2014–2021 (USD Billion)
Table 32 Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 33 NGS Market Size, By Region, 2014–2021 (USD Billion)
Table 34 North America: NGS Market Size, By Country, 2014–2021 (USD Billion)
Table 35 APAC: NGS Market Size, By Country/Region, 2014–2021 (USD Billion)
Table 36 Quantitative Pcr Market Size, By Region, 2014–2021 (USD Billion)
Table 37 North America: Quantitative Pcr Market Size, By Country, 2014–2021 (USD Billion)
Table 38 APAC: Quantitative Pcr Market Size, By Country/Region, 2014–2021 (USD Billion)
Table 39 Immunohistochemistry Market Size, By Region, 2014–2021 (USD Billion)
Table 40 North America: Immunohistochemistry Market Size, By Country, 2014–2021 (USD Billion)
Table 41 APAC: Immunohistochemistry Market Size, By Country/Region, 2014–2021 (USD Billion)
Table 42 In Situ Hybridization Market Size, By Region, 2014–2021 (USD Billion)
Table 43 North America: in Situ Hybridization Market Size, By Country, 2014–2021 (USD Billion)
Table 44 APAC: in Situ Hybridization Market Size, By Country/Region, 2014–2021 (USD Billion)
Table 45 Microarrays Market Size, By Region, 2014–2021 (USD Billion)
Table 46 North America: Microarrays Market Size, By Country, 2014–2021 (USD Billion)
Table 47 APAC: Microarrays Market Size, By Country/Region, 2014–2021 (USD Billion)
Table 48 Tumor Profiling Market Size, By Region, 2014–2021 (USD Billion)
Table 49 North America: Tumor Profiling Market Size, By Country, 2014–2021 (USD Billion)
Table 50 North America: Tumor Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 51 North America: Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 52 North America: Tumor Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 53 U.S.: Tumor Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 54 U.S.: Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 55 U.S.: Tumor Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 56 Canada: Tumor Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 57 Canada: Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 58 Canada: Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 59 Europe: Cancer Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 60 Europe: Cancer Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 61 Europe: Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 62 APAC: Cancer Profiling Market Size, By Country, 2014–2021 (USD Billion)
Table 63 APAC: Cancer Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 64 APAC: Cancer Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 65 APAC: Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 66 China: Cancer Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 67 China: Cancer Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 68 China: Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 69 Japan: Cancer Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 70 Japan: Cancer Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 71 Japan: Cancer Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 72 RoAPAC: Tumor Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 73 RoAPAC: Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 74 RoAPAC: Tumor Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 75 RoW: Tumor Profiling Market Size, By Application, 2014–2021 (USD Billion)
Table 76 RoW: Tumor Profiling Market Size, By Technique, 2014–2021 (USD Billion)
Table 77 RoW: Tumor Profiling Market Size, By Technology, 2014–2021 (USD Billion)
Table 78 Product Launches, 2013–2016
Table 79 Agreements, Collaborations, and Partnerships, 2013–2016
Table 80 Acquisitions, 2013–2016
Table 81 Other Strategies, 2013–2016


List of Figures (34 Figures)

Figure 1 Research Design
Figure 2 Cancer Profiling Market top Down Approach
Figure 3 Cancer Profiling Market: Bottom Up Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Healthcare Expenditure Across Major Countries: 2000 vs 2014
Figure 7 Cancer Profiling Market Snapshot, 2016 vs 2021
Figure 8 Global Cancer Profiling Market Size, By Application, 2016 vs 2021
Figure 9 Global Cancer Profiling Market Size, By Technique, 2016 vs 2021
Figure 10 Global Cancer Profiling Market Size, By Technology, 2016 vs 2021
Figure 11 Geographical Snapshot of the Cancer Profiling Market
Figure 12 Cancer Profiling Market to Register A Double-Digit Growth Rate During the Forecast Period
Figure 13 Genomics to Dominate the Cancer Profiling Market in 2016
Figure 14 Next-Generation Sequencing to Witness the Highest CAGR in the Forecast Period
Figure 15 Personalized Medicine Will Continue to Dominate the Tumor Profiling Market in 2021
Figure 16 Asia-Pacific to Witness the Highest Growth From 2016 to 2021
Figure 17 Tumor Profiling Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Increasing Number of New Cancer Cases Worldwide (2012 vs 2015 vs 2020)
Figure 19 New Cancer Cases, By Country (2012)
Figure 20 New Cancer Cases, By Country (2020)
Figure 21 The Personalized Medicine Application Segment is Expected to Dominate the Market During the Forecast Period
Figure 22 The Genomics Segment to Dominate the Market During the Forecast Period
Figure 23 NGS Segment to Dominate the Cancer Profiling Market in the Forecast Period
Figure 24 Cancer Profiling Market: Geographic Snapshot
Figure 25 North America: Market Snapshot
Figure 26 Asia-Pacific: Market Snapshot
Figure 27 Companies Majorly Pursued the Strategy of Product Launch Between 2013 and 2016
Figure 28 Geographic Revenue Mix of the Prominent Players in the Cancer Profiling Market
Figure 29 Company Snapshot: Illumina, Inc.
Figure 30 Company Snapshot: Qiagen N.V.
Figure 31 Company Snapshot: Neogenomics Laboratories, Inc.
Figure 32 Company Snapshot: HTG Molecular Diagnostics, Inc.
Figure 33 Company Snapshot: Genomic Health Inc.
Figure 34 Company Snapshot: Nanostring Technologies, Inc.

The global cancer/tumor profiling market is projected to reach USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016, growing at a CAGR of 19.1% during the forecast period.

Growth in the cancer profiling market is driven by the increasing number of cancer cases, growing utility of biomarker in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

The cancer profiling market is segmented on the basis of application, technique, technology, and region. Based on application, the market is segmented into personalized medicine, biomarker discovery, diagnostics, prognostics, and research applications. Based on technique, the market is divided into genomics, proteomics, epigenetics, and metabolomics. Based on technology, the market is segmented into next-generation sequencing, quantitative PCR, in situ hybridization, immunohistochemistry, and microarray. The next-generation sequencing segment is expected to account for the largest market share in 2016. The large share of this segment can be attributed to the reduction in sequencing costs, technology advancements in sequencing platforms, research laboratories and academicians promoting the use of NGS, and increasing awareness on NGS products and services are contributing to the growth of this segment.

Cancer/Tumor Profiling Market

North America is expected to account for the largest share of the cancer profiling market in 2016. Increasing research funding and presence of a large number of market players and research institutes are propelling the growth of the North American cancer profiling market. However, the Asia-Pacific region is estimated to witness the highest growth during the forecast period. The Asia-Pacific region is expected to grow at the highest CAGR of 20.4% in the forecast period. In recent years, the Asia-Pacific market for cancer profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.

Major players operating in the cancer profiling market include Illumina Inc. (U.S.), QIAGEN N.V. (Netherlands), NeoGenomics Laboratories (U.S.), HTG Molecular Diagnostic (U.S.), and Genomic Health Inc. (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Medical Devices Markets on KnowledgeStore
Request Demo